Nanjing King-Friend Biochemical PharmaceuticalLtd Second Quarter 2024 Earnings: EPS: CN¥0.14 (vs CN¥0.18 in 2Q 2023)

Simply Wall St · 09/01 01:52

Nanjing King-Friend Biochemical PharmaceuticalLtd (SHSE:603707) Second Quarter 2024 Results

Key Financial Results

  • Revenue: CN¥1.14b (up 14% from 2Q 2023).
  • Net income: CN¥227.8m (down 22% from 2Q 2023).
  • Profit margin: 20% (down from 29% in 2Q 2023). The decrease in margin was driven by higher expenses.
  • EPS: CN¥0.14 (down from CN¥0.18 in 2Q 2023).
earnings-and-revenue-growth
SHSE:603707 Earnings and Revenue Growth September 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Nanjing King-Friend Biochemical PharmaceuticalLtd Earnings Insights

Looking ahead, revenue is forecast to grow 23% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 4.0% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Nanjing King-Friend Biochemical PharmaceuticalLtd you should know about.